Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

1
Player Avatar rainmaker59 (52.75) Submitted: 11/11/2009 9:29:44 PM : Outperform Start Price: $6.32 ELN Score: +45.16

Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.

Report this Post 1 Reply
Member Avatar wanttobelieve (< 20) Submitted: 12/15/2009 12:03:48 AM
Recs: 0

They are a poorly run company that cannot even produce their own drugs

Report this Post

Featured Broker Partners


Advertisement